DURECT (NASDAQ:DRRX) Posts Quarterly Earnings Results, Misses Estimates By $0.12 EPS

DURECT (NASDAQ:DRRX) announced its earnings results on Wednesday. The specialty pharmaceutical company reported ($0.06) earnings per share for the quarter, missing analysts’ consensus estimates of $0.06 by ($0.12), Zacks reports. The firm had revenue of $2.30 million for the quarter, compared to the consensus estimate of $6.91 million. DURECT had a negative return on equity of 300.62% and a negative net margin of 198.58%.

DURECT Stock Performance

DRRX opened at $0.81 on Friday. The firm has a market cap of $25.02 million, a P/E ratio of -1.32 and a beta of 0.91. The business’s fifty day moving average is $0.80 and its 200-day moving average is $1.01. DURECT has a 52-week low of $0.70 and a 52-week high of $1.88.

Wall Street Analysts Forecast Growth

A number of equities research analysts have recently weighed in on DRRX shares. StockNews.com assumed coverage on DURECT in a report on Thursday. They set a “sell” rating for the company. HC Wainwright reissued a “neutral” rating on shares of DURECT in a report on Thursday.

About DURECT

DURECT Corporation, a biopharmaceutical company, develops medicines based on its epigenetic regulator program. The company's lead product larsucosterol (DUR-928), an endogenous, orally bioavailable small molecule that is in Phase IIb clinical trial to play a regulatory role in lipid metabolism, stress and inflammatory responses, and cell death and survival to treat alcohol-associated hepatitis, as well as completed Phase Ib clinical trial to treat patients with nonalcoholic steatohepatitis.